Bright minds is unaware of any material changes

Vancouver, british columbia--(newsfile corp. - october 15, 2024) - at the request of ciro, bright minds biosciences inc. (cse: drug) (nasdaq: drug) ("bright minds" or the "company") wishes to confirm that the company's management is unaware of any material changes in the company's operations that would account for the recent increase in market activity. about bright minds bright minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
DRUG Ratings Summary
DRUG Quant Ranking